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Abstract 
Background: It has been previously postulated that high phenylalanine (Phe) might disturb intracerebral dopamine 
production, which is the main regulator of prolactin secretion in the pituitary gland. Previously, various associations 
between Phe and hyperprolactinemia were revealed in studies performed in phenylketonuria (PKU) children and ado-
lescents. The aim of the present study was to clarify whether any relation between serum phenylalanine and prolactin 
levels can be found in adult PKU patients.
Patients and methods: We conducted a cross-sectional, monocentric study including 158 adult patients (male 
n = 68, female n = 90) with PKU. All patients were diagnosed during newborn screening and were treated since 
birth. Serum Phe, tyrosine (Tyr), prolactin (PRL), and thyroid-stimulating hormone (TSH) levels were measured, and 
Phe/Tyr ratio was calculated. Males and females were analyzed separately because the serum prolactin level is 
gender-dependent.
Results: No significant correlations were found between serum phenylalanine, tyrosine, or the Phe/Tyr ratio and 
serum prolactin level either in the male or in the female group.
Conclusions: In treated adult PKU patients, the serum prolactin level may not be significantly influenced by Phe or 
Tyr serum levels.
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Background
Phenylketonuria (PKU, OMIM: 261600) is the most com-
mon amino acid metabolism disorder. In PKU, the defi-
ciency of the hepatic enzyme phenylalanine hydroxylase 
(PAH) causes elevated serum phenylalanine (Phe) with 
normal to low tyrosine (Tyr) levels. Untreated PKU leads 
to mental retardation, psychiatric, and various neuro-
logical disorders beyond other complications in affected 
patients. To achieve the best outcomes, PKU patients 
need a Phe-low diet and lifelong Phe-free amino acid 
substitution. In some cases, sapropterin therapy can ease 
the diet limitation [1].
High phenylalanine impairs intracerebral neuro-
transmitter availability in multiple ways [2, 3]. On the 
one hand, Phe can competitively inhibit rate-limiting 
enzymes in the synthesis of various transmitters (e.g., 
tyrosine-3 hydroxylase and tryptophan-5-hydroxylase). 
On the other hand, Phe blocks the transport of transmit-
ter precursors at the neutral amino acid transporter of 
the blood–brain barrier (BBB) [4–6]. A recent study with 
rodent PKU model confirmed these pathophysiological 
disturbances [7]. A study by de Groot et al. showed that 
increased blood Phe concentrations are associated with 
reduced blood-to-brain Tyr transport and decreased 
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intracerebral Tyr availability for neurotransmitter synthe-
sis [8].
Obtaining information about the intracerebral neuro-
transmitter state in PKU is relevant, since the results can 
influence the treatment strategy. However, direct exami-
nation of intracerebral transmitter concentration or 
availability is not feasible in daily practice. For research 
purposes, measuring dopamine or its metabolites from 
intracerebral fluid is possible, but only in selective cases 
and not as a routine [9]. Therefore, surrogate markers are 
highly needed that can make a diagnostic impact of the 
intracerebral neurotransmitter effect in PKU.
Prolactin (luteotropic hormone, PRL), a protein hor-
mone, is synthesized in the anterior pituitary, and its 
main action is the initiation and maintenance of lacta-
tion. Pituitary prolactin secretion is decisively regulated 
through the tonic inhibitory effect of dopamine secreted 
from the hypothalamic tuberoinfundibular neurons in 
the arcuate and periventricular nuclei (A12, 14) [10]. 
Intracerebral dopamine deficiency results in hyperprol-
actinemia [11].
In PKU, hyperphenylalaninemia can influence the 
intracerebral transformation of tyrosine to l-dihy-
droxyphenylalanine (l-DOPA), which is subsequently 
converted to dopamine [12]. Previous investigations pre-
sumed that elevated Phe levels can increase prolactin 
secretion through reduced intracerebral dopamine avail-
ability [13–15].
Clinical studies performed among children or adoles-
cents have investigated the association between Phe and 
prolactin in PKU, but the results were conflicting [6, 12, 
16].
Therefore, our aim was to assess whether an associa-
tion between Phe and PRL exists in adult PKU patients.
Patients and methods
Patients
In a monocentric, cross-sectional study, 158 adult 
patients with PKU were consecutively enrolled between 
January 2014 and March 2015 at the Semmelweis Univer-
sity, Budapest, Hungary. All patients were diagnosed dur-
ing the neonatal screening program, and their treatment 
was initiated from birth. Patients were regularly exam-
ined at the 2nd Department of Medicine, Semmelweis 
University, Budapest, Hungary.
Patients with conditions affecting prolactin secretion 
(pregnancy, breast feeding, thyroid or pituitary disor-
ders, use of contraceptive pills, or drugs known to influ-
ence prolactin secretion) were excluded. All procedures 
followed were in accordance with the ethical standards 
of the responsible committee on human experimenta-
tion (Semmelweis University) and with the Helsinki 
Declaration of 1975, and the study was approved by the 
Hungarian ethical committee (ETT TUKEB (Medical 
Research Council Scientific and Research Committee): 
reference number: 5075-2/2014/EKU). Informed consent 
was obtained from all patients for being included in the 
study.
From the 158 PKU adults, 90 patients were female 
and 68 were male. The mean age was 30.4 ±  6.1  years. 
According to the Hungarian PKU Guidelines, the recom-
mended upper target Phe concentration for adulthood is 
600 μmol/l. None of the patients were treated with BH4.
Methods
All blood samples were drawn from the antecubital vein 
under standardized conditions in fasting state between 
08:00 and 10:00 a.m. Phenylalanine and tyrosine lev-
els were measured by API2000 LC/MS/MS at the 1st 
Department of Pediatrics. The serum concentration of 
prolactin was determined at the Central Laboratory of 
Semmelweis University using a chemi-immunometric 
assay (CMIA, Abbott Architect, Abbott Park, USA). TSH 
was also checked in order to rule out the TRH-induced 
hyperprolactinemia using this chemi-immunometric 
assay (CMIA, Abbott Architect, Abbott Park, USA). In 
a few elevated prolactin samples, PEG precipitation was 
used to detect macroprolactin. The reference values for 
prolactin were 1.4–24 ng/ml in female, 1.6–10.7 ng/ml in 
males; for TSH was 0.35–4.9 mU/l.
Statistics
For association studies, Spearman’s rho correlation coef-
ficients was used. For analyzing the differences between 
different subgroups, Mann–Whitney non-parametric 
tests were used. Since data were not normally distributed, 
results are reported as median (minimum–maximum) 
values. All statistical analysis were performed using SPSS 
version 23 (IBM Corp. in Armonk, NY, USA).
Results
The median levels were as follows: Phe: 619 (124–1259) 
μmol/l; Tyr: 54 (21–169) μmol/l. The Phe/Tyr ratio was 
11 (1.6–43.7). The prolactin level was 12 (3–75) ng/ml in 
the whole studied population. All study participants had 
normal TSH results.
Since the serum prolactin level is gender-dependent, 
our patient group was divided into male and female 
groups and the associations were studied separately. 
Patient characteristics are included in Table  1. The 
median age of the female group was 32 (18–49) years, 
while in the male group, it was 31 (19–44) years. The 
median concentrations of Phe, Tyr, and PRL were as fol-
lows: Female group, Phe: 574 (124–1221) μmol/l, Tyr: 45 
(21–169) μmol/l; PRL: 14 (5–75) ng/ml; Male group, Phe: 
642 (253–1259) μmol/l, Tyr: 55 (24–127) μmol/l; PRL: 9 
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(4–47) ng/ml. None of the patients had prolactin-related 
complaints or symptoms, such as menstrual irregularity, 
galactorrhea, or erectile dysfunction.
It has to be mentioned that in the female group the 
median Phe concentration was slightly below, whereas in 
the male group the median Phe level was slightly above 
the recommended upper target Phe concentration for 
adulthood (600  μmol/l). Comparing the gender groups, 
males had significantly higher Phe levels (p = 0.018), but 
the Tyr level (p = 0.120) and the Phe/Tyr ratio (p = 0.274) 
did not differ significantly between groups.
The highest prolactin value was 75 ng/ml, but this level 
alone without any clinical complaint does not represent 
a requirement for further endocrinological investiga-
tions. In samples showing a higher PRL concentration, 
PEG precipitation was used to detect macroprolactin, but 
none of these samples were found to be positive.
In the male group, neither phenylalanine nor tyros-
ine serum concentration, nor the Phe/Tyr ratio, showed 
any correlation with serum prolactin level. No associa-
tion between Phe, Tyr, the Phe/Tyr ratio, and PRL was 
observed in female patients. The correlation coefficients 
are presented in Table 2. Figure 1a, b shows the relation-
ships between Phe and PRL in the female and in the male 
subgroups.
Dividing our patients groups into quartiles based on 
the Phe level, no significant differences in prolactin con-
centration were observed (Table  3). In the male group, 
the lowest Phe-quartile was not significantly different 
from the highest Phe-quartile (p = 0.366). In the female 
group, the lowest Phe-quartile was also not significantly 
different from the highest Phe-quartile (p = 0.532).
Discussion
Prolactin is unique among the pituitary gland hormones 
because its secretion is mainly under negative tonic inhi-
bition by hypothalamic dopamine [10]. Since dopamine 
biosynthesis begins from tyrosine, and its intracerebral 
availability depends on phenylalanine metabolism, it was 
hypothesized that prolactin secretion might be altered by 
the hyperphenylalaninemia observed in PKU.
To date, only three studies involving a relatively small 
study population evaluated the relationship between Phe 
and PRL in PKU. On the other hand, these studies were 
performed in children and adolescents. Schulpis et  al. 
found a positive correlation between Phe and PRL serum 
levels [16], but Denecke et al. did not confirm these asso-
ciations [6]. In the study by Schulpis et al., girls with high 
Phe levels complained of irregular menstruation, suggest-
ing that other underlying diseases might be responsible 
for the increased PRL level [16]. Recently, van Vliet et al. 
examined the effect of BH4-treatment on prolactin secre-
tion in a few BH4-responsive male PKU patients. Their 
findings revealed that prolactin concentration positively 
correlated with blood Phe level, and the BH4-treatment 
lowered the Phe and PRL levels [12].
Our data obtained in a larger number of adult PKU 
patients showed no correlation between Phe and prolac-
tin serum concentration. In addition, neither phenylala-
nine, tyrosine nor the Phe/Tyr ratio correlated with the 
prolactin concentration.
To interpret our results, we should take into account 
more factors. First, the Phe level in the total and also in 
the gender-specific subgroups was around the upper limit 
established for adults (600 μmol/l). One might think that 
very high Phe levels (>1000  μmol/l, representing “loose 
diet” patients) can increase the prolactin level. Therefore, 
we divided our treated patients into different quartiles 
based on Phe concentration and compared the PRL con-
centration between these subgroups. Again, no signifi-
cant differences in prolactin level was detected. It should 
be highlighted that the studied population had some die-
tary restrictions that lowered serum Phe concentration. 
An optimal comparison would be with a group of PKU 
patients absolutely free of diet control.
Second, PKU itself is not a homogeneous disease, as the 
mutation and the enzyme activity influence the severity 
of PKU. However, enzyme activity determination is not 
Table 1 Median age and  serum concentration of  Phe, Tyr, 
Phe/Tyr, TSH, and PRL in adult patients with PKU
TSH normal range 0.35–4.9 mU/l; Prolactin: female: 1.4–24 ng/ml; male: 
1.6–10.7 ng/ml
Female Male
Number of patients 90 68
Age [years] (min–max) 32 (18–49) 31 (19–44)
Phe [μmol/l] (min–max) 574 (124–1221) 642 (253–1259)
Tyr [μmol/l] (min–max) 45 (21–169) 55 (24–127)
Phe/Tyr 11.9 (1.6–43.7) 11 (2.4–39.5)
Prolactin [ng/ml] (min–max) 14 (5–75) 9 (4–47)
TSH [mU/l] (min–max) 1.5 (0.6–4.3) 1.1 (0.4–4.9)
Table 2 Correlation coefficients and  p values 
between  serum prolactin and  Phe-Tyr levels in  adult 
patients with PKU
Spearman’s rho correlation analysis. The significance level was set at 0.01
Female Male
Correlation  
coefficient
p  
value
Correlation  
coefficient
p 
value
Phe −0.082 0.478 0.177 0.230
Tyr 0.065 0.580 −0.231 0.114
Phe/Tyr −0.134 0.251 0.252 0.084
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a realistic goal in all PKU patients, whereas comparing 
the hormone results according to the PAH gene mutation 
might reveal novel associations.
We also found that the tyrosine serum level did not cor-
relate with the prolactin level. It is known that the serum 
Tyr level has relatively large diurnal fluctuations [17] 
mediated by diet and the phenylalanine-free protein sub-
stitutes used by patients. Therefore, the calculation with 
one sample concentration may not be enough to detect a 
possible correlation with prolactin. However, using blood 
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Fig. 1 a Graphical presentation of the Phe-PRL relationship in the female PKU adult subgroup. b Graphical presentation of the Phe-PRL relationship 
in the male PKU adult subgroup
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samples drawn in standardized fasting conditions may 
eliminate the majority of these problems. Furthermore, 
the serum Tyr concentration cannot reflect the intrac-
erebral Tyr concentration, which is the precursor of the 
intracerebral catecholamine synthesis. Hyperphenylala-
ninemia negatively influence dopamine utilization in the 
brain by competitive inhibition of the LNAA transporter 
and by reduced activity of DOPA decarboxylase [18]. 
Although there are data showing that the serum Phe level 
could correspondingly represent brain Phe concentration 
in PKU with great inter-individual variability [19, 20], no 
study performed in humans has been published that can 
give us an estimation of the suppressive effect of intracer-
ebral Phe concentration on dopamine synthesis. Another 
limitation of our study may be that we did not take into 
account the menstrual cycle. However, the serum PRL 
level shows only minor fluctuations during the menstrual 
cycle, and therefore, this fluctuation may have a limited 
role in this current study. It should be mentioned that 
the strength of our study is the relatively high number of 
adult patients.
Conclusion
Taken together, we found no correlation between serum 
Phe and prolactin in a relatively large, treated adult PKU 
population.
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